Hospitalization Endpoint in Clinical Trials of Outpatient Settings: using Anti-SARS-COV-2 Therapy as an Example

References

• Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427
   PubMed Web of Science ®Google Scholar
• Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Interna Health. 2020;25(3):278–280. doi:10.1111/tmi.13383
   PubMed Web of Science ®Google Scholar
• Hoseinpour Dehkordi A, Alizadeh M, Derakhshan P, Babazadeh P, Jahandideh A. Understanding epidemic data and statistics: a case study of COVID‐19. J Med Virol. 2020;92(7):868–882. doi:10.1002/jmv.25885
   PubMed Web of Science ®Google Scholar
• Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging. 2020;12(10):9959. doi:10.18632/aging.103344
   PubMedGoogle Scholar
• Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7. doi:10.1016/S1473-3099(20)30483-7
   PubMed Web of Science ®Google Scholar
• Tong A, Elliott JH, Azevedo LC, et al. Core outcomes set for trials in people with coronavirus disease 2019. Crit Care Med. 2020;48(11):1622. doi:10.1097/CCM.0000000000004585
   PubMed Web of Science ®Google Scholar
• Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382–1392. doi:10.1056/NEJMoa2102685
   PubMed Web of Science ®Google Scholar
• Gupta AK, Rojas YG, Juarez E, et al. 502. early COVID-19 treatment with SARS-CoV-2 neutralizing ANTIBODY SOtrovimab. In: Open Forum Infectious Diseases. N Engl J Med. 2021;385:1941–50.
   Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients. MedRxiv. 2021;1:1.
   Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Bhosale V, Reddy H, et al. Phase III, randomized, double-blind, placebo controlled trial of efficacy, safety and tolerability of antiviral drug umifenovir vs standard care of therapy in non-severe COVID-19 patients. Inter J Infect Dis. 2022;115:62–69. doi:10.1016/j.ijid.2021.11.025
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315. doi:10.1056/NEJMoa2116846
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, da Silva MM G, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Dabbous HM, El-Sayed MH, El Assal G, et al. RETRACTED ARTICLE: safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: a randomised controlled trial. Sci Rep. 2021;11(1):1–7. doi:10.1038/s41598-020-79139-8
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, Phase 3 clinical trial. Inter J Infect Dis. 2021;103:62–71. doi:10.1016/j.ijid.2020.11.142
   PubMed Web of Science ®Google Scholar
• Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2021;76(3):753–757. doi:10.1093/jac/dkaa501
   PubMed Web of Science ®Google Scholar
• Reis G, Dos SM SEA, Silva DCM, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Network Open. 2021;4(4):e216468–e216468. doi:10.1001/jamanetworkopen.2021.6468
   PubMed Web of Science ®Google Scholar
• Nourian A, Khalili H, Ahmadinejad Z, et al. Efficacy and safety of sofosbuvir/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Bio Medica: Atenei Parmensis. 2020;91(4):1.
   Google Scholar
• Keene ON, Lynggaard H, Englert S, Lanius V, Wright D. Why estimands are needed to define treatment effects in clinical trials. BMC Med. 2023;21(1):276. doi:10.1186/s12916-023-02969-6
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726–732. doi:10.7326/0003-4819-152-11-201006010-00232
   PubMed Web of Science ®Google Scholar
• Lepage L, Altman DG, Schulz KF, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663–694. doi:10.7326/0003-4819-134-8-200104170-00012
   PubMed Web of Science ®Google Scholar
• Sakamaki K, Uemura Y, Shimizu Y. Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov. Trials. 2021;22(1). doi:10.1186/s13063-021-05763-y
   PubMed Web of Science ®Google Scholar
• Dodd LE, Follmann D, Wang J, et al. Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clin Trial. 2020;17(5):472–482. doi:10.1177/1740774520939938
   PubMed Web of Science ®Google Scholar
• Step. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2023; Available from: www.ema.europa.eu/contact. Accessed 2023 Aug 29.
   Google Scholar